A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
Status:
Recruiting
Trial end date:
2022-08-20
Target enrollment:
Participant gender:
Summary
The subsequent treatment choices for the patients with advanced melanoma, who have failed the
immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1
signalling pathways are not redundant. Blocking both of them could produce synergistic
effect. HX008 and LP002 are humanized monoclonal antibodies targeting PD-1 on T cells and
PD-L1 on tumor cells respectively. In this study, participants with locally advanced or
metastatic melanoma who have failed previous anti-PD-1 or PD-L1 will be administrated with
HX008 plus LP002. The safety and preliminary efficacy will be evaluated.